tacrolimus (Q411648)

PubChem

PubChem CID

445643

tacrolimus (English)

18 November 2016

5 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=L04AD02

5 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=L04AD02

World Health Organisation international non-proprietary name

tacrolimus (English)

2 references

tacrolimus (anhydrous) (English)

19 October 2016

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

tacrolimusum (Latin)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

tacrolimus (French)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

tacrólimus (Spanish)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

такролимус (Russian)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

تاكروليموس (Arabic)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

他克莫司 (Chinese)

1 reference

2 September 2019

https://mednet-communities.net/inn/db/ViewINN.aspx?i=6878

found in taxon

Streptomyces hygroscopicus

1 reference

Enhancement of ascomycin production via a combination of atmospheric and room temperature plasma mutagenesis in Streptomyces hygroscopicus and medium optimization

Streptomyces tacrolimicus

1 reference

Characterisation of a γ-butyrolactone receptor of Streptomyces tacrolimicus: effect on sporulation and tacrolimus biosynthesis

Streptomyces clavuligerus

2 references

Liquid chromatography-mass spectrometry characterization of FK506 biosynthetic intermediates in Streptomyces clavuligerus KCTC 10561BP.

Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor

Penicillium

1 reference

Amino Acid Conjugated Anthraquinones from the Marine-Derived Fungus Penicillium sp. SCSIO sof101.

medical condition treated

1 reference

graft-versus-host disease

13 December 2016

2 references

13 December 2016

2 October 2018

lupus nephritis

1 reference

interstitial lung disease

2 October 2018

1 reference

2 October 2018

conjunctivitis

1 reference

acute graft versus host disease

2 October 2018

1 reference

2 October 2018

lichen planus

1 reference

2 October 2018

autoimmune hepatitis

1 reference

2 October 2018

ulcerative colitis

1 reference

2 October 2018

nephrotic syndrome

1 reference

2 October 2018

polymyositis

1 reference

2 October 2018

myasthenia gravis

1 reference

2 October 2018

vitiligo

1 reference

significant drug interaction

2 October 2018

valganciclovir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ganciclovir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

foscarnet

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pentamidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

foscarnet

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pentamidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ranolazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

voriconazole

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

fosphenytoin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atazanavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

saquinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluconazole

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

molecular function

FK506 binding

0 references

physically interacts with

FKBP prolyl isomerase 1A

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

6784

intravenous infusion and defusion

17 August 2016

route of administration

oral administration

0 references

0 references

legal status (medicine)

boxed warning

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category C

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

1 reference

https://www.pfizer.com/products/product-list

1 reference

5 March 2018

immunosuppressive drug

0 references

Commons category

Tacrolimus

0 references

Identifiers

J9U ID

987007549156305171

1 reference

National Library of Israel

Library of Congress authority ID

sh94005977

1 reference

https://github.com/JohnMarkOckerbloom/ftl/blob/master/data/wikimap

InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

3 April 2019

InChI

1 reference

tacrolimus (English)

18 November 2016

2 references

tacrolimus (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

104987-11-3

2 references

Global Substance Registration System

UNII

Y5L2157C4J

tacrolimus anhydrous (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=104987-11-3

9 April 2021

1 reference

Tacrolimus (English)

18 November 2016

2 references

tacrolimus (English)

18 November 2016

Reaxys registry number

3647477

1 reference

tacrolimus (anhydrous) (English)

19 October 2016

8821611

1 reference

tacrolimus (anhydrous) (English)

19 October 2016

ChEBI ID

61049

mapping relation type

2 references

TACROLIMUS (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

1 reference

TACROLIMUS (English)

18 November 2016

2 references

inferred from InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

Tacrolimus (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.155.367

27 December 2018

ECHA Substance Infocard ID

(3S,4R,5R,8R,9Z,12R,14S,15R,16S,18R,19R,26aS)-8-allyl-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone (English)

quotation

CAS no.: 104987-11-3 (English)

100.155.367

1 reference